NCT01209208View on ClinicalTrials.gov

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Lymphocytic Colitis
Interventions
DRUG

Budesonide

9 mg per day

DRUG

Mesalamine

3 g per day

OTHER

Placebo

0 g per day

Trial Locations (1)

Unknown

Magen-Darm-Zentrum, IKE - Internistische Kooperation Eppendorf, Hamburg

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY